Main pancreatic duct (MPD) dilation without an apparent obstructing lesion is an independent risk factor for neoplastic ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug ...

ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive ...

A Bolton nurse, from Wigan, has expressed gratitude to those who donated to support her during her breast cancer journey this year ...

Oncolytics Biotech ( ($ONCY) ) has shared an update. Oncolytics Biotech Inc. announced on November 19, 2025, that it has aligned with the FDA on ...

Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030 ...

FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment paradigms for ...

This retrospective cohort study used data from the Veterans Health Administration to assess the association between chronic untreated HCV and incident PDAC and whether different HCV genotypes affect ...

Pinned between the stomach and spine, the pancreas supervises both digestion and blood sugar in the body. It's also the site ...

NUS Medicine-led study shows extracellular vesicles carrying gene-targeting antisense oligonucleotides (ASOs) and immune ...

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ('PDAC”), ...

Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS ...